Northland Securities Comments on MiMedx Group Q1 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Equities researchers at Northland Securities issued their Q1 2026 earnings estimates for shares of MiMedx Group in a note issued to investors on Tuesday, January 20th. Northland Securities analyst C. Byrnes expects that the company will post earnings per share of $0.02 for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at $0.12 EPS.

MDXG has been the topic of several other reports. Wall Street Zen upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 2nd. Lake Street Capital decreased their price objective on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Finally, Mizuho cut their price target on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 17th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Price Performance

Shares of MDXG stock opened at $5.42 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. MiMedx Group has a 12-month low of $5.13 and a 12-month high of $9.30. The firm has a fifty day moving average of $6.62 and a 200-day moving average of $6.88. The firm has a market capitalization of $802.70 million, a price-to-earnings ratio of 20.07 and a beta of 1.57.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, October 29th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.07 by $0.08. The firm had revenue of $113.73 million during the quarter, compared to the consensus estimate of $94.74 million. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%.

Insider Buying and Selling at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of MiMedx Group stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the sale, the insider owned 236,982 shares of the company’s stock, valued at approximately $1,758,406.44. The trade was a 19.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.70% of the stock is owned by insiders.

Institutional Investors Weigh In On MiMedx Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC raised its position in MiMedx Group by 63.8% during the second quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after acquiring an additional 1,892 shares in the last quarter. Legato Capital Management LLC boosted its stake in shares of MiMedx Group by 18.5% during the 3rd quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock worth $121,000 after acquiring an additional 2,708 shares during the period. HighMark Wealth Management LLC boosted its stake in shares of MiMedx Group by 5.4% during the 3rd quarter. HighMark Wealth Management LLC now owns 55,878 shares of the company’s stock worth $390,000 after acquiring an additional 2,878 shares during the period. SkyView Investment Advisors LLC increased its holdings in shares of MiMedx Group by 3.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after acquiring an additional 3,032 shares during the last quarter. Finally, Rafferty Asset Management LLC raised its stake in MiMedx Group by 5.2% in the 3rd quarter. Rafferty Asset Management LLC now owns 66,240 shares of the company’s stock valued at $462,000 after acquiring an additional 3,262 shares during the period. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.